FDG for therapy of metabolically active tumors

Sridivya Jaini, Ekaterina Dadachova

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

18F-2-deoxy-2-fluoro-d-glucose ( 18F-FDG, later referred to as 19FDG) has been extensively used in diagnostic positron emission tomography (PET) in oncology for many years. FDG is a glucose analog that is taken by cells in a similar fashion as glucose and is phosphorylated by hexokinase to 18F-FDG-6-phosphate but cannot undergo further glycolysis, and hence is trapped in the cell. Metastatic cancer remains a major cause of death men and women, surpassed only by heart disease. Despite the enormous research efforts resulting in emergence of novel drug candidates, there is little progress in improving the survival of patients with many types of solid tumors. Thus, novel therapies to combat metastatic cancer are urgently needed. With a physical half-life of almost 2 hours, 18F emits energetic positrons with high abundance (96%) and a path length in tissue of ∼0.1-0.2 cm. Theoretically, these positrons can kill cancer cells in the same manner as electrons by damaging DNA and cellular machinery and inducing apoptosis/necrosis of the tumor cells. Several years ago, we explored, in a first series of comprehensive studies, the therapeutic potential of FDG in experimental breast cancer and showed its efficacy and safety. Since then, FDG therapy has been shown to be effective and safe in experimental melanoma, colon cancer, as well as in eliminating in vitro the endothelial cells in blood vessels, which supply the tumors with nutrients. The next step forward in translation of FDG therapy into the clinic should be a phase II clinical trial. Also, recent developments in targeted PET imaging could increase the range of PET pharmaceuticals potentially useful for positron therapy of metastatic cancers because of increased specificity of these tracers in comparison with FDG.

Original languageEnglish (US)
Pages (from-to)185-189
Number of pages5
JournalSeminars in Nuclear Medicine
Volume42
Issue number3
DOIs
StatePublished - May 2012

Fingerprint

Neoplasms
Positron-Emission Tomography
Electrons
Fluorodeoxyglucose F18
Glucose
Therapeutics
Phase II Clinical Trials
Experimental Melanomas
Hexokinase
Glycolysis
Pharmaceutical Preparations
Colonic Neoplasms
Blood Vessels
Half-Life
Cause of Death
Heart Diseases
Necrosis
Endothelial Cells
Phosphates
Apoptosis

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

FDG for therapy of metabolically active tumors. / Jaini, Sridivya; Dadachova, Ekaterina.

In: Seminars in Nuclear Medicine, Vol. 42, No. 3, 05.2012, p. 185-189.

Research output: Contribution to journalArticle

Jaini, Sridivya ; Dadachova, Ekaterina. / FDG for therapy of metabolically active tumors. In: Seminars in Nuclear Medicine. 2012 ; Vol. 42, No. 3. pp. 185-189.
@article{74c97521aa0b421e920174e8344e85ca,
title = "FDG for therapy of metabolically active tumors",
abstract = "18F-2-deoxy-2-fluoro-d-glucose ( 18F-FDG, later referred to as 19FDG) has been extensively used in diagnostic positron emission tomography (PET) in oncology for many years. FDG is a glucose analog that is taken by cells in a similar fashion as glucose and is phosphorylated by hexokinase to 18F-FDG-6-phosphate but cannot undergo further glycolysis, and hence is trapped in the cell. Metastatic cancer remains a major cause of death men and women, surpassed only by heart disease. Despite the enormous research efforts resulting in emergence of novel drug candidates, there is little progress in improving the survival of patients with many types of solid tumors. Thus, novel therapies to combat metastatic cancer are urgently needed. With a physical half-life of almost 2 hours, 18F emits energetic positrons with high abundance (96{\%}) and a path length in tissue of ∼0.1-0.2 cm. Theoretically, these positrons can kill cancer cells in the same manner as electrons by damaging DNA and cellular machinery and inducing apoptosis/necrosis of the tumor cells. Several years ago, we explored, in a first series of comprehensive studies, the therapeutic potential of FDG in experimental breast cancer and showed its efficacy and safety. Since then, FDG therapy has been shown to be effective and safe in experimental melanoma, colon cancer, as well as in eliminating in vitro the endothelial cells in blood vessels, which supply the tumors with nutrients. The next step forward in translation of FDG therapy into the clinic should be a phase II clinical trial. Also, recent developments in targeted PET imaging could increase the range of PET pharmaceuticals potentially useful for positron therapy of metastatic cancers because of increased specificity of these tracers in comparison with FDG.",
author = "Sridivya Jaini and Ekaterina Dadachova",
year = "2012",
month = "5",
doi = "10.1053/j.semnuclmed.2011.12.001",
language = "English (US)",
volume = "42",
pages = "185--189",
journal = "Seminars in Nuclear Medicine",
issn = "0001-2998",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - FDG for therapy of metabolically active tumors

AU - Jaini, Sridivya

AU - Dadachova, Ekaterina

PY - 2012/5

Y1 - 2012/5

N2 - 18F-2-deoxy-2-fluoro-d-glucose ( 18F-FDG, later referred to as 19FDG) has been extensively used in diagnostic positron emission tomography (PET) in oncology for many years. FDG is a glucose analog that is taken by cells in a similar fashion as glucose and is phosphorylated by hexokinase to 18F-FDG-6-phosphate but cannot undergo further glycolysis, and hence is trapped in the cell. Metastatic cancer remains a major cause of death men and women, surpassed only by heart disease. Despite the enormous research efforts resulting in emergence of novel drug candidates, there is little progress in improving the survival of patients with many types of solid tumors. Thus, novel therapies to combat metastatic cancer are urgently needed. With a physical half-life of almost 2 hours, 18F emits energetic positrons with high abundance (96%) and a path length in tissue of ∼0.1-0.2 cm. Theoretically, these positrons can kill cancer cells in the same manner as electrons by damaging DNA and cellular machinery and inducing apoptosis/necrosis of the tumor cells. Several years ago, we explored, in a first series of comprehensive studies, the therapeutic potential of FDG in experimental breast cancer and showed its efficacy and safety. Since then, FDG therapy has been shown to be effective and safe in experimental melanoma, colon cancer, as well as in eliminating in vitro the endothelial cells in blood vessels, which supply the tumors with nutrients. The next step forward in translation of FDG therapy into the clinic should be a phase II clinical trial. Also, recent developments in targeted PET imaging could increase the range of PET pharmaceuticals potentially useful for positron therapy of metastatic cancers because of increased specificity of these tracers in comparison with FDG.

AB - 18F-2-deoxy-2-fluoro-d-glucose ( 18F-FDG, later referred to as 19FDG) has been extensively used in diagnostic positron emission tomography (PET) in oncology for many years. FDG is a glucose analog that is taken by cells in a similar fashion as glucose and is phosphorylated by hexokinase to 18F-FDG-6-phosphate but cannot undergo further glycolysis, and hence is trapped in the cell. Metastatic cancer remains a major cause of death men and women, surpassed only by heart disease. Despite the enormous research efforts resulting in emergence of novel drug candidates, there is little progress in improving the survival of patients with many types of solid tumors. Thus, novel therapies to combat metastatic cancer are urgently needed. With a physical half-life of almost 2 hours, 18F emits energetic positrons with high abundance (96%) and a path length in tissue of ∼0.1-0.2 cm. Theoretically, these positrons can kill cancer cells in the same manner as electrons by damaging DNA and cellular machinery and inducing apoptosis/necrosis of the tumor cells. Several years ago, we explored, in a first series of comprehensive studies, the therapeutic potential of FDG in experimental breast cancer and showed its efficacy and safety. Since then, FDG therapy has been shown to be effective and safe in experimental melanoma, colon cancer, as well as in eliminating in vitro the endothelial cells in blood vessels, which supply the tumors with nutrients. The next step forward in translation of FDG therapy into the clinic should be a phase II clinical trial. Also, recent developments in targeted PET imaging could increase the range of PET pharmaceuticals potentially useful for positron therapy of metastatic cancers because of increased specificity of these tracers in comparison with FDG.

UR - http://www.scopus.com/inward/record.url?scp=84859342075&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859342075&partnerID=8YFLogxK

U2 - 10.1053/j.semnuclmed.2011.12.001

DO - 10.1053/j.semnuclmed.2011.12.001

M3 - Article

VL - 42

SP - 185

EP - 189

JO - Seminars in Nuclear Medicine

JF - Seminars in Nuclear Medicine

SN - 0001-2998

IS - 3

ER -